tiprankstipranks
Trending News
More News >
Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
Australian Market
Advertisement

Lumos Diagnostics Holdings Ltd. (LDX) AI Stock Analysis

Compare
9 Followers

Top Page

AU:LDX

Lumos Diagnostics Holdings Ltd.

(Sydney:LDX)

Rating:57Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
The stock's score is impacted mainly by financial performance risks, including profitability challenges and high leverage. Technical analysis provides some positive outlook with strong market momentum, though overbought signals present caution. Valuation remains a concern due to negative earnings and lack of dividends.

Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)

Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model

Company DescriptionLumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
How the Company Makes MoneyLumos Diagnostics generates revenue primarily through the sale of its proprietary point-of-care diagnostic products. The company designs and manufactures these products, which are then distributed to healthcare providers, clinics, and laboratories. In addition to direct sales, Lumos Diagnostics may also engage in strategic partnerships and collaborations with other healthcare organizations to co-develop or distribute diagnostic solutions. These partnerships can involve revenue sharing, licensing agreements, or joint ventures that contribute to the company's income. Another potential revenue stream for Lumos Diagnostics is offering contract development and manufacturing services to third parties, leveraging its expertise and technology in the diagnostic field.

Lumos Diagnostics Holdings Ltd. Financial Statement Overview

Summary
Lumos Diagnostics is experiencing revenue growth but faces profitability challenges with negative net income and high leverage. The gross profit margin improvement is positive, but overall financial risk remains due to negative cash flow and high debt-to-equity ratio.
Income Statement
60
Neutral
Lumos Diagnostics Holdings Ltd. has shown some revenue growth over the periods, with an increase from $11.1M to $14.7M in the TTM. However, the company has struggled with profitability as evidenced by negative net and EBIT margins. The gross profit margin has improved to around 63.9% in the TTM, indicating good cost management, but net income remains negative, affecting overall profitability.
Balance Sheet
40
Negative
The company's balance sheet reveals a high debt-to-equity ratio of approximately 0.80 in the TTM, which indicates significant leverage. Stockholders' equity has decreased over time, and the equity ratio is moderately low at about 36.9%, suggesting reliance on debt financing. The company needs to improve its equity position to enhance financial stability.
Cash Flow
50
Neutral
The cash flow statement shows negative free cash flow in the TTM, reflecting ongoing operational challenges. However, there has been some improvement in cash flow from operations compared to previous periods. The operating cash flow to net income ratio is nominally negative, highlighting cash flow issues. The company needs to focus on generating positive free cash flow to sustain operations without relying heavily on external financing.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue11.13M10.54M11.63M18.85M5.79M
Gross Profit7.10M5.97M4.46M8.60M2.51M
EBITDA-5.44M-4.93M-18.67M-10.69M-10.41M
Net Income-8.59M-8.97M-45.72M-15.03M-9.28M
Balance Sheet
Total Assets26.84M25.42M36.94M97.99M30.28M
Cash, Cash Equivalents and Short-Term Investments6.48M3.02M7.98M44.89M850.93K
Total Debt8.06M9.79M7.19M7.20M3.24M
Total Liabilities19.73M15.92M19.05M39.71M8.12M
Stockholders Equity7.11M9.50M17.89M58.28M22.16M
Cash Flow
Free Cash Flow848.00K-9.79M-22.39M-16.77M-10.28M
Operating Cash Flow946.00K-9.64M-18.04M-10.89M-3.76M
Investing Cash Flow-98.00K4.31M-4.36M-8.33M-6.52M
Financing Cash Flow2.63M652.00K-10.92M63.27M8.12M

Lumos Diagnostics Holdings Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.07
Price Trends
50DMA
0.03
Positive
100DMA
0.03
Positive
200DMA
0.03
Positive
Market Momentum
MACD
<0.01
Negative
RSI
82.47
Negative
STOCH
67.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:LDX, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 82.47 is Negative, neither overbought nor oversold. The STOCH value of 67.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:LDX.

Lumos Diagnostics Holdings Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
AU$45.66M-51.49%80.84%57.59%
52
Neutral
$7.61B0.04-62.94%2.44%16.14%0.33%
45
Neutral
AU$25.25M-104.23%-17.26%
45
Neutral
AU$90.86M-47.52%44.61%16.40%
45
Neutral
AU$42.14M-39.07%26.07%0.85%
40
Underperform
AU$15.39M-71.10%76.17%
38
Underperform
AU$49.44M-33.42%158.37%36.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.07
0.02
40.00%
AU:BDX
BCAL Diagnostics Limited
0.07
-0.05
-41.67%
AU:RHY
Rhythm Biosciences Ltd.
0.05
>-0.01
-16.67%
AU:GSS
Genetic Signatures Ltd.
0.36
-0.40
-52.63%
AU:IIQ
Inoviq Ltd
0.38
-0.22
-36.67%
AU:MAP
Microba Life Sciences Limited
0.10
-0.10
-50.00%

Lumos Diagnostics Holdings Ltd. Corporate Events

Lumos Diagnostics Releases Informational Presentation with Investment Disclaimers
Jul 21, 2025

Lumos Diagnostics Holdings Ltd. has released a presentation intended for informational purposes, emphasizing that it should not form the basis of any investment decisions. The document contains disclaimers about the accuracy and reliability of the information provided, highlighting that it includes forward-looking statements subject to risks and uncertainties. The company advises stakeholders to seek independent professional advice before making investment decisions, as the document is not a prospectus or an offer to acquire securities.

Lumos Diagnostics Reports Revenue Growth and Strategic Developments in Q4 FY25
Jul 20, 2025

Lumos Diagnostics reported a 12% increase in FY25 revenue, reaching US$12.4 million, despite a 26% quarterly revenue drop due to the end of the U.S. flu season. The company is advancing its FebriDx CLIA Waiver Study and has secured a significant distribution agreement with PHASE Scientific in the U.S. Additionally, Lumos has expanded its development agreement with Hologic, which is expected to generate additional revenue, and secured a loan facility to support working capital needs.

Lumos Diagnostics Announces Proposed Securities Issue
Jul 17, 2025

Lumos Diagnostics Holdings Ltd. has announced a proposed issue of 19,616,000 ordinary fully paid securities, with the issuance date set for September 1, 2025. This strategic move is expected to bolster the company’s financial position, potentially enhancing its market competitiveness and providing additional resources for its ongoing projects and initiatives.

Lumos Diagnostics Secures A$5 Million Loan and Major Distribution Deal
Jul 17, 2025

Lumos Diagnostics has secured a A$5.0 million loan facility from major shareholders Tenmile Ventures and Ryder Capital to support its efforts in obtaining a CLIA waiver for its FebriDx® product from the FDA. This financial move is part of a broader strategy to maintain momentum towards commercialization while minimizing equity dilution. Additionally, Lumos has entered into a significant distribution agreement with PHASE Scientific, valued at US$317 million, contingent upon achieving the CLIA waiver. This agreement marks one of the largest distribution deals for an ASX-listed diagnostics company and is expected to provide substantial funding alongside the loan facility to meet Lumos’s working capital needs.

Lumos Diagnostics Releases Informational Briefing for Investors
Jul 16, 2025

Lumos Diagnostics Holdings Ltd. has released an investor briefing document, emphasizing that the information provided is solely for informational purposes and not intended as a basis for investment decisions. The document includes disclaimers regarding the accuracy and reliability of the information, highlighting the inherent risks and uncertainties in market data and forward-looking statements. Lumos advises recipients to seek independent professional advice before making investment decisions, as the document does not constitute financial advice.

Lumos Diagnostics Announces U.S. Distribution Deal for FebriDx
Jul 16, 2025

Lumos Diagnostics Holdings Ltd, a leader in rapid point-of-care diagnostic technologies, has announced an exclusive U.S. distribution agreement for its FebriDx product with PHASE Scientific. This strategic partnership is expected to enhance Lumos’s market presence in the U.S., potentially improving its operational capabilities and offering significant benefits to its stakeholders.

Lumos Diagnostics Resumes Trading Post Strategic Agreement
Jul 16, 2025

Lumos Diagnostics Holdings Limited, listed on the Australian Securities Exchange, has announced the lifting of its trading suspension following the release of a significant strategic agreement. This development is expected to have a positive impact on the company’s market operations and stakeholder confidence, as it signifies a potential turning point in its strategic positioning.

Lumos Diagnostics Secures Major U.S. Distribution Deal for FebriDx®
Jul 16, 2025

Lumos Diagnostics has signed a significant six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® product in the U.S. market, valued at up to US$317 million. This agreement marks a pivotal moment for Lumos, as it provides a clear pathway for FebriDx® to enter the U.S. market, pending a CLIA waiver from the FDA. The partnership with PHASE Scientific, known for its rapid diagnostics brand INDICAID®, is expected to enhance the adoption of FebriDx® in urgent care settings, potentially transforming rapid respiratory diagnostics and clinical decision-making.

Lumos Diagnostics Requests Suspension of Securities for Strategic Announcement
Jul 14, 2025

Lumos Diagnostics Holdings Ltd. has requested a voluntary suspension of its securities on the Australian Securities Exchange pending a significant announcement related to strategic material agreements. This suspension is intended to help the company manage its disclosure obligations, with expectations to release the announcement before the next trading session, potentially impacting its market positioning and stakeholder interests.

Lumos Diagnostics Initiates Trading Halt Ahead of Strategic Announcement
Jul 11, 2025

Lumos Diagnostics Holdings Ltd. has requested a trading halt on its securities on the Australian Securities Exchange pending an announcement related to strategic material agreements. This move is intended to manage the company’s continuous disclosure obligations and is expected to conclude by the start of normal trading on July 15, 2025, or upon the release of the announcement. The trading halt reflects the company’s proactive approach to compliance and transparency, potentially impacting its market positioning and stakeholder interests.

Lumos Diagnostics Announces Cessation of Certain Securities
Jul 2, 2025

Lumos Diagnostics Holdings Ltd. announced the cessation of certain securities due to unmet conditions or expiration. This development may impact the company’s capital structure and could influence investor perceptions, as it reflects on the company’s ability to meet certain financial or operational milestones.

Lumos Diagnostics Secures R&D Tax Rebate to Boost Innovation
Jun 23, 2025

Lumos Diagnostics has received a cash refund of A$215,485 under the Australian Government’s Research and Development Tax Incentive for its FY2024 efforts. This refund supports Lumos’ ongoing R&D in enhancing its diagnostic technology platform, which is crucial for securing partnerships and advancing point-of-care technologies.

Lumos Diagnostics Achieves Key Milestone in FebriDx Clinical Study
Jun 18, 2025

Lumos Diagnostics has achieved a significant milestone in its FebriDx CLIA waiver clinical study by enrolling its 500th patient, triggering a milestone payment from its partner BARDA. The study aims to secure a CLIA waiver from the U.S. FDA, which would allow broader use of FebriDx in various healthcare settings, potentially unlocking a U.S. market exceeding $1 billion. With the study expected to conclude by Q4 2025, Lumos plans to submit its CLIA waiver application in October 2025, which could enhance point-of-care decision-making and antibiotic stewardship in the U.S. healthcare system.

Lumos Diagnostics’ FebriDx to Aid Antimicrobial Stewardship Trial
Jun 17, 2025

Lumos Diagnostics has announced that its FebriDx point-of-care test will be used in the University of Wollongong’s OPTIMAS-GP Trial, which aims to reduce unnecessary antibiotic prescribing for respiratory infections in primary care settings. This trial, funded by the Australian Government’s Medical Research Future Fund, will evaluate the feasibility and acceptability of FebriDx in Australian general practice, marking its first formal evaluation in this setting. The initiative is part of a broader effort to combat antimicrobial resistance by promoting evidence-based clinical decisions, and Lumos will provide approximately 2,000 test kits at a reduced cost.

Lumos Diagnostics Announces Change of Business Address
Jun 2, 2025

Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, has announced a change in its registered office and principal place of business to a new address in Melbourne, Australia. This move is part of the company’s ongoing efforts to streamline its operations and enhance its market presence, with all other contact details remaining unchanged.

Lumos Diagnostics Expands Medicare Coverage for FebriDx®
May 26, 2025

Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx® test from a sixth Medicare Administrative Contractor (MAC), CGS Administrators, which covers Kentucky and Ohio. This achievement means Lumos now has reimbursement coverage from six out of seven MACs, representing over 85% of US Medicare payment coverage, significantly expanding its access to the Medicare patient population. This development is a critical milestone for Lumos, as Medicare often sets a precedent for private insurance payors, and it demonstrates the company’s commitment to achieving nationwide access and broad clinical adoption of FebriDx.

Lumos Diagnostics Expands Medicare Coverage for FebriDx Test
May 19, 2025

Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx test from a fifth Medicare Administrative Contractor (MAC), WPS Health Solutions, retroactive from May 1, 2025. This achievement means Lumos now has coverage from five of the seven MACs, covering over 70% of US Medicare payments, which significantly enhances its access to the Medicare patient population. The company is actively negotiating with the remaining two MACs and aims to secure reimbursement from private insurers, striving for nationwide access and broad clinical adoption of FebriDx.

Lumos Diagnostics Secures Major FebriDx Order from iMedical
May 13, 2025

Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, has announced a significant purchase order for its FebriDx test from iMedical, Inc., marking the largest single order since the test’s launch. This order underscores the growing acceptance and demand for FebriDx in the US market, following its FDA clearance in July 2023 for aiding in the diagnosis of bacterial acute respiratory infections. The collaboration with iMedical, a company known for providing cost-saving solutions to healthcare facilities, is expected to enhance the market presence of FebriDx and improve health outcomes through advanced point-of-care technology.

Lumos Diagnostics Issues 23 Million Performance Rights
May 9, 2025

Lumos Diagnostics Holdings Ltd. announced the issuance of 23,000,000 unquoted performance rights as part of an employee incentive scheme. This move is aimed at enhancing employee motivation and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and market positioning positively.

Lumos Diagnostics Releases Q3 FY25 Investor Briefing
May 6, 2025

Lumos Diagnostics Holdings Ltd. has released an investor briefing for Q3 FY25, emphasizing that the information is solely for informational purposes and not intended as a basis for investment decisions. The document highlights the company’s focus on providing diagnostic solutions, but it also includes disclaimers regarding the accuracy and reliability of the information, emphasizing the inherent risks and uncertainties in market data and forecasts.

Lumos Diagnostics Reports Strong Q3 FY25 Revenue Growth and Strategic Advances
Apr 29, 2025

Lumos Diagnostics reported a revenue of US$3.5 million for the third quarter of FY25, marking a 21% increase from the previous quarter, although down 13% from the same period last year. The company saw significant growth in its services and product revenues, with notable developments including new distribution partnerships for FebriDx® in the U.S. and the expansion of the Hologic fFN project. The company also achieved successful audit results for its quality management system, and FebriDx® was added to the Medicare Fee Schedule, potentially enhancing its market reach.

Lumos Diagnostics Expands Medicare Coverage for FebriDx®
Apr 23, 2025

Lumos Diagnostics has secured additional U.S. Medicare reimbursement coverage for its FebriDx® test from two more Medicare Administrative Contractors (MACs), First Coast Service Options and Noridian Healthcare Solutions. This achievement expands Lumos’ Medicare coverage to four out of seven MACs, covering over 55% of U.S. Medicare payments. This milestone is crucial for the commercial success of FebriDx, as Medicare adoption often influences private insurance payors’ decisions. Lumos continues to pursue coverage from the remaining MACs and private payors to achieve nationwide access and support broad clinical adoption.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025